Loading...

Brilliant Violet 711™ anti-human CD45RA Antibody

Pricing & Availability
Clone
HI100 (See other available formats)
Regulatory Status
RUO
Workshop
IV N906
Other Names
GP180, L-CA, LCA, LY5, T200, PTPRC
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
HI100_BV711_061512
Human peripheral blood lymphocytes stained with CD45RA (clone HI100) Brilliant Violet 711™.
  • HI100_BV711_061512
    Human peripheral blood lymphocytes stained with CD45RA (clone HI100) Brilliant Violet 711™.
See Brilliant Violet 711™ spectral data
Cat # Size Price Quantity Check Availability Save
304137 25 tests 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304138 100 tests 348€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45RA is a 205-220 kD single chain type I glycoprotein. It is an exon 4 splice variant of the tyrosine phosphatase CD45. The CD45RA isoform is expressed on resting/naïve T cells, medullary thymocytes, B cells and monocytes. CD45RA enhances both T cell receptor and B cell receptor signaling. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4. CD45 has also been reported to bind galectin-1. CD45 isoform expression can change in response to cytokines.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for relevant formats of this clone) include: inhibition of CD45 functions2, immunohistochemical staining of frozen tissue sections3 and formalin-fixed paraffin-embedded tissue sections4, and immunocytochemistry15,16.

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Yamada T, et al. 2002. J. Biol. Chem. 277:28830. (WB, Block)
  3. Weninger W, et al. 2003 J. Immunol. 170:4638. (IHC-F)
  4. Imanguli MM, et al. 2009. Blood. 113:3620 (IHC-P)
  5. Roque S, et al. 2007. J. Immunol. 178:8028. (FC) PubMed
  6. Smeltz RB. 2007. J. Immunol. 178:4786. (FC) PubMed
  7. Palendira U, et al. 2008. Blood (FC) PubMed
  8. Kuttruff S, et al. 2009. Blood 113:358. (FC) PubMed
  9. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  10. Alanio C, et al. 2010. Blood 115:3718. (FC) PubMed
  11. Iannello A, et al. 2010. J. Immunol. 184:114. (FC) PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Guereau-de-Arellan M, et al. 2011. Brain. 134:3578. PubMed
  14. Canque B, et al. 2000. Blood 96:3748. (ICC)
  15. Imanguli MM, et al. 2009. Blood 13:3620. (ICC)
  16. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Schofield L, et al. 2017. BMC Med. 10.1186/s12916-017-0883-8. PubMed
  2. Amelio P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005817. PubMed
  3. Baxter AE, et al. 2017. Nat Protoc. 12:2029. PubMed
  4. Lu YC, et al. 2018. Cell Rep. 25:2083. PubMed
  5. Barcelo H, et al. 2018. Curr Protoc Cytom. 84:e35. PubMed
  6. Thyagarajan B, et al. 2018. J Immunol Methods. 463:61. PubMed
  7. Gupta R, et al. 2020. Cell Stem Cell. 26:527. PubMed
  8. Abd Hamid M, et al. 2020. Cancer Immunology Research. 8(2):203-216. PubMed
  9. Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed
  10. Nielsen CM, et al. 2021. Cell Reports Medicine. 2(3):100207. PubMed
  11. Crump NT, et al. 2021. Cell Reports. 35(6):109101. PubMed
  12. Richardson SE, et al. 2021. STAR Protocols. 2(2):100420. PubMed
  13. Duhen R, et al. 2021. Nat Commun. 12:1047. PubMed
  14. Pagel J, et al. 2020. Front Immunol. 11:565257. PubMed
  15. NULL, et al. 2022. Cell. 185:916. PubMed
  16. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  17. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  18. Port JR, et al. 2020. J Virol. 94:. PubMed
  19. Tulyeu J, et al. 2021. Curr Protoc. 1:e283. PubMed
  20. Li L, et al. 2022. JCI Insight. 7:. PubMed
  21. Vanuytsel K, et al. 2022. Cytometry A. 101:903. PubMed
  22. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  23. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  24. Gao F, et al. 2023. Immunity. 56:864. PubMed
  25. Woodcock V, et al. 2023. BJUI Compass. 4:322. PubMed
  26. Bhatia V, et al. 2023. Nat Commun. 14:2041. PubMed
RRID
AB_11218999 (BioLegend Cat. No. 304137)
AB_2563815 (BioLegend Cat. No. 304138)

Antigen Details

Structure
Tyrosine phosphatases, type I transmembrane (exon 4 splicing of CD45 gene), 205-220 kD
Distribution

B cells, naïve T cells, monocytes

Function
Enhances TCR and BCR signaling
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, Monocytes, T cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.

Gene ID
5788 View all products for this Gene ID
UniProt
View information about CD45RA on UniProt.org
Go To Top Version: 2    Revision Date: 07.25.2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account